Trial Profile
A Single-Center Evaluation of the Relative Efficacy of EM-100 Compared to Zaditor® (Ketotifen Fumarate Ophthalmic Solution 0.035%) and Vehicle in the Treatment of Ocular Itching Associated With Allergic Conjunctivitis as Induced by the Conjunctival Allergen Challenge Model (Ora-CAC®)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 19 May 2021
Price :
$35
*
At a glance
- Drugs EM 100 (Primary) ; Ketotifen (Primary)
- Indications Allergic conjunctivitis
- Focus Therapeutic Use
- Sponsors Bausch & Lomb
- 01 Aug 2018 New trial record
- 24 Jul 2018 Primary endpoint has been met. (Ocular itching), as reported in an Eton Pharma Media Release.
- 24 Jul 2018 Results published in an Eton Pharma Media Release